Yousif Capital Management LLC Has $3.34 Million Stake in Shockwave Medical, Inc. (NASDAQ:SWAV)

Yousif Capital Management LLC cut its stake in Shockwave Medical, Inc. (NASDAQ:SWAV) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,507 shares of the company’s stock after selling 322 shares during the period. Yousif Capital Management LLC’s holdings in Shockwave Medical were worth $3,336,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in SWAV. Wellington Management Group LLP boosted its position in shares of Shockwave Medical by 33.5% during the third quarter. Wellington Management Group LLP now owns 1,805,771 shares of the company’s stock worth $359,529,000 after buying an additional 453,048 shares during the period. Artisan Partners Limited Partnership raised its holdings in shares of Shockwave Medical by 21.8% in the third quarter. Artisan Partners Limited Partnership now owns 1,398,136 shares of the company’s stock valued at $278,369,000 after purchasing an additional 250,352 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Shockwave Medical by 35.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 645,634 shares of the company’s stock worth $128,546,000 after purchasing an additional 170,369 shares in the last quarter. Canada Pension Plan Investment Board boosted its holdings in Shockwave Medical by 66.7% during the third quarter. Canada Pension Plan Investment Board now owns 386,321 shares of the company’s stock worth $76,917,000 after purchasing an additional 154,637 shares during the last quarter. Finally, International Assets Investment Management LLC grew its position in Shockwave Medical by 18,122.1% in the fourth quarter. International Assets Investment Management LLC now owns 141,586 shares of the company’s stock valued at $26,981,000 after purchasing an additional 140,809 shares in the last quarter. Institutional investors own 95.35% of the company’s stock.

Insider Transactions at Shockwave Medical

In other Shockwave Medical news, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $287.67, for a total value of $1,150,680.00. Following the transaction, the insider now directly owns 56,818 shares of the company’s stock, valued at approximately $16,344,834.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, VP Trinh Phung sold 1,287 shares of Shockwave Medical stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $232.18, for a total transaction of $298,815.66. Following the completion of the sale, the vice president now directly owns 32,933 shares of the company’s stock, valued at approximately $7,646,383.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Isaac Zacharias sold 4,000 shares of the business’s stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $287.67, for a total value of $1,150,680.00. Following the completion of the sale, the insider now owns 56,818 shares of the company’s stock, valued at $16,344,834.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 89,813 shares of company stock worth $22,863,919. 3.40% of the stock is owned by insiders.

Shockwave Medical Stock Performance

Shares of NASDAQ SWAV opened at $330.00 on Monday. Shockwave Medical, Inc. has a 12 month low of $157.00 and a 12 month high of $331.58. The stock has a 50 day moving average of $294.88 and a 200-day moving average of $233.64. The company has a current ratio of 11.76, a quick ratio of 10.73 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $12.34 billion, a P/E ratio of 85.27, a P/E/G ratio of 2.45 and a beta of 0.92.

Shockwave Medical (NASDAQ:SWAV) last released its quarterly earnings data on Thursday, February 15th. The company reported $1.16 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.24. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The firm had revenue of $202.98 million during the quarter, compared to analysts’ expectations of $199.43 million. During the same period in the previous year, the business posted $3.71 earnings per share. The company’s revenue for the quarter was up 41.0% compared to the same quarter last year. As a group, equities research analysts predict that Shockwave Medical, Inc. will post 4.94 EPS for the current year.

Analyst Ratings Changes

Several brokerages have commented on SWAV. TheStreet raised shares of Shockwave Medical from a “c+” rating to a “b” rating in a research report on Thursday, February 15th. CL King reissued a “neutral” rating on shares of Shockwave Medical in a research report on Monday, April 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $335.00 price objective (up previously from $270.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Finally, Piper Sandler raised their target price on shares of Shockwave Medical from $290.00 to $360.00 and gave the company an “overweight” rating in a research note on Tuesday, April 2nd. Ten investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, Shockwave Medical presently has a consensus rating of “Hold” and an average price target of $309.11.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.